These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19207325)

  • 1. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study.
    Mest DR; Humble GM
    Dermatol Surg; 2009 Feb; 35 Suppl 1():350-9. PubMed ID: 19207325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience.
    Mest DR; Humble G
    Dermatol Surg; 2006 Nov; 32(11):1336-45. PubMed ID: 17083585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.
    Moyle GJ; Brown S; Lysakova L; Barton SE
    HIV Med; 2006 Apr; 7(3):181-5. PubMed ID: 16494632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid.
    Mest DR; Humble GM
    Aesthetic Plast Surg; 2009 Jul; 33(4):654-6. PubMed ID: 18704558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
    Burgess CM; Quiroga RM
    J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging.
    Hanke CW; Redbord KP
    J Drugs Dermatol; 2007 Feb; 6(2):123-8. PubMed ID: 17373169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable poly-L-lactic acid for human immunodeficiency virus-associated facial lipoatrophy: cumulative year 2 interim analysis of an open-label study (FACES).
    Bassichis B; Blick G; Conant M; Condoluci D; Echavez M; Eviatar J; Gold MH; Hamilton T; Hanke CW; Humble G; LaMarca A; Daro-Kaftan E; Mest D; Pierone G
    Dermatol Surg; 2012 Jul; 38(7 Pt 2):1193-205. PubMed ID: 22759256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolution of injectable poly-L-lactic acid from the correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies.
    Burgess C
    J Drugs Dermatol; 2011 Sep; 10(9):1001-6. PubMed ID: 22052268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study.
    Levy RM; Redbord KP; Hanke CW
    J Am Acad Dermatol; 2008 Dec; 59(6):923-33. PubMed ID: 19022099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review.
    Kates LC; Fitzgerald R
    Aesthet Surg J; 2008; 28(4):397-403. PubMed ID: 19083552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly-L-lactic acid: a new dimension in soft tissue augmentation.
    Rotunda AM; Narins RS
    Dermatol Ther; 2006; 19(3):151-8. PubMed ID: 16784514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
    Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
    Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
    Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigator global evaluations of efficacy of injectable poly-L-lactic acid versus human collagen in the correction of nasolabial fold wrinkles.
    Brandt FS; Cazzaniga A; Baumann L; Fagien S; Glazer S; Kenkel JM; Lowe NJ; Monheit GD; Narins RS; Rendon MI; Rohrich RJ; Werschler WP
    Aesthet Surg J; 2011 Jul; 31(5):521-8. PubMed ID: 21719865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semipermanent filler treatment of HIV-positive patients with facial lipoatrophy: long-term follow-up evaluating MR imaging and quality of life.
    van Rozelaar L; Kadouch JA; Duyndam DA; Nieuwkerk PT; Lutgendorff F; Karim RB
    Aesthet Surg J; 2014 Jan; 34(1):118-32. PubMed ID: 24334306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies.
    Barton SE; Engelhard P; Conant M
    Int J STD AIDS; 2006 Jul; 17(7):429-35. PubMed ID: 16820069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly-L-lactic acid: a perspective from my practice.
    Sadick NS
    J Cosmet Dermatol; 2008 Mar; 7(1):55-60. PubMed ID: 18254813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly-L-lactic acid.
    Perry CM
    Am J Clin Dermatol; 2004; 5(5):361-6; discussion 367-8. PubMed ID: 15554738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly-L-lactic acid for facial lipoatrophy in HIV.
    El-Beyrouty C; Huang V; Darnold CJ; Clay PG
    Ann Pharmacother; 2006 Sep; 40(9):1602-6. PubMed ID: 16912248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring.
    Lam SM; Azizzadeh B; Graivier M
    Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):55S-63S. PubMed ID: 16936545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.